A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment with Subcutaneous Abatacept in Combination with Methotrexate versus Subcutaneous Adalimumab in Combination with Methotrexate in Adults with Early Rheumatoid Arthritis who are Naive to Biologic Disease-Modifying Antirheumatic Drugs

The immune system of patients with Rheumatoid Arthritis (RA) is different from that of people who do not have RA. The purpose of this study is to examine your immune cells and proteins before you start to take study medication and after you start treatment with one of two approved therapies for RA, abatacept versus adalimumab, both given in combination with methotrexate. This study will also check whether characteristics of your immune system assessed before you receive any study drug affect your response to the study drug received.

Primary Sponsor:
BMS

Prinicipal Investigator:
Adey Berhanu, MD

Contact Phone:
202-994-8567

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):